anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intensive Care Unit-acquired weakness (ICU-AW) is a common complication that significantly impedes patient recovery. In the study, we investigated the correlation between early serum myoglobin levels in patients with septic shock due to pneumonia, and the incidence of ICU-AW, duration of mechanical ventilation, and prognosis. Patients were classified based on the development of ICU-AW within the first 10 days of ICU admission. We measured serum myoglobin levels upon ICU entry, and analyzed demographic data, APACHE II scores, use of mechanical ventilation, and clinical outcomes, including mortality and duration of mechanical ventilation. The results indicated significantly elevated serum myoglobin levels in the ICU-AW group, correlated with prolonged mechanical ventilation and increased mortality. ROC analysis revealed myoglobin as a promising biomarker for predicting ICU-AW, with an area under the curve of 0.843 (95% CI: 0.819~0.867), demonstrating a sensitivity of 76.00% and specificity of 82.30%. These findings underscored serum myoglobin as a predictive biomarker for early ICU-AW in septic shock patients, highlighting its potential to guide clinical decision-making.
To provide an eyewear device that can be used for storage, slow release, and replenishment of a therapeutic drug without interfering with vision of a user.SOLUTION: An eyewear device includes a main body, at least one storage area, and at least one microflow passage. The main body comprises a first surface, a second surface, a center, a first outer edge of the first surface, and a second outer edge of the second surface. The storage area is installed in the main body, and used to be filled with a drug. The microflow passage is installed near the first outer edge of the first surface or the second outer edge of the second surface. One end of the microflow passage is connected to the storage area, and fills the storage area with the drug. Another end of the microflow passage faces an opening of a periphery of the eyewear device, and comes into contact with a cornea and/or a sclera. In addition, the opening, the first outer edge of the first surface, and the second outer edge of the second surface are connected to one another.SELECTED DRAWING: Figure 1-1
Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
PURPOSE:To provide a hair cosmetic capable of moderately controlling the metabolic reaction in the scalp tissue and effectively suppressing the dandruff, by using vitamin E acetate which is available at a low cost and safe to the skin. CONSTITUTION:The objective hair cosmetic contains 0.5-10.0wt% (preferably 1.0-10.0wt%) vitamin E acetate. The vitamin E acetate is safe to the skin in contrast with antibacterial agents. It is a viscous, amorphous oily substance generally soluble in oils, fats, paraffins, organic solvents, etc., and insoluble or hardly soluble in water or aqueous organic solvent. It can be compounded to a cosmetic composition by conventional method for the compounding of ordinary oily substance. The hair cosmetic is used in the form of hair tonic, hair liquid, milky lotion for scalp, hair cream, hair shampoo, etc.
Fine spherical particles with satisfactory molecular orientation which are based on film formation of a bola-form compound and are useful in the field of fine chemicals such as functional materials and medical materials, the electronic/information field, etc.; spherical microcapsules having a hydrophilic core substance encapsulated therein; and processes for producing the spherical particles and the microcapsules. The fine spherical particles can be produced by immersing a hydrophilic substrate in an aqueous solution of a salt of a compound represented by the following general formula (1) and precipitating fine particles in an acid atmosphere. (1) (In the formula, R represents hydrogen or C1-5 alkyl; n is an integer of 8 to 20; and m is an integer of 1 to 3.) The spherical microcapsules having a hydrophilic core substance encapsulated therein can be produced by immersing a hydrophilic substrate in an aqueous solution of both a salt of a compound represented by the general formula (1) and a hydrophilic core substance and precipitating fine particles in an acid atmosphere. The fine spherical particles and spherical microcapsules obtained have a particle diameter of 0.01 to 100 µm.
PURPOSE:To provide a skin cosmetic containing a thermally non-coagulable yolk, giving smooth feeling to the skin, having moisturizing effect, emollient effect and skin activating effect and imparting springiness and luster to the skin. CONSTITUTION:A thermally non-coagulable yolk is produced by selectively removing proteins participating in thermal coagulation from yolk of bird, e.g. chicken, quail, wild duck, turkey, etc., especially yolk of chicken's egg. For example, 1pt. of egg yolk is added with 3-5pts. of water (which may contain 3-25wt% ethyl alcohol) and is stirred to effect the selective coagulation of the above protein, the coagulum is separated from the mixture and the obtained yolk solution is optionally heat-treated at >=80 deg.C to obtain the thermally non- coagulable yolk. The product is preferably condensed or dried and compounded to a skin cosmetic to obtain the objective skin cosmetic having the above effects. The amount of the non-coagulable protein is preferably 0.001-20wt%, especially 0.1-10wt% based on the whole composition in terms of solid.
PURPOSE:A composition for oral administration, containing a vitamin D3 having the hydroxylated 1alpha-position as an active constituent and useful for treating inflammatory keratosis and dyskeratosis, e.g. psoriasis, etc. CONSTITUTION:A composition, containing vitamin D3 having the hydroxylated 1alpha-position, preferably 1alpha,25-dihydroxyvitamin D3 or 1alpha-hydroxyvitamin D3, etc. and useful for treating inflammatory keratosis and dyskeratosis, e.g. psoriasis, parapsoriasis, lichen ruber, pityriasis rubra pilaris, Darier's disease, etc. The composition is administered by forming an oily solution perpared by dissolving the vitamin D3 in an oily base into a soft capsule and the dose thereof is 0.3-3.0mug/day for oral administration.
The invention provides a processing technology of honey-making rehmannia root, which adopts low-temperature and vacuum mode. Concretely, the invention has the following steps: a. the medicament of raw material. b. the preliminary processing of fresh rehmannia root. c. the medicament of sugar liquor and the immersion of rehmannia root. d. the medicament of the rehmannia root and honey. e. drying and packing. The invention basically keeps the original nutritional components of the rehmannia root and the honey, meanwhile, the invention   improves taste of the rehmannia root, the honey-making rehmannia root which is made has the following effects: <1> heat-clearing, nourishing Yin, body fluid regenerating, blood nourishing, blood cooling, blood pressure lowering, and heart rate decreasing. <2> the invention can inhibit little liquid in stool, duodenal ulcer, conjunctivitis, and child cold-dysentery and the like. <3> the invention has a certain curative effects to insomnia and headache. <4> the invention has certain functions to infected wound, burn, and frost-injury. <5> the invention has the function of beauty.
Subjects will be given syringes containing placebo. Injections will be given subcutaneously, one time per week for 52 weeks.
This is the first evaluation of the efficacy of a mindfulness-based intervention for insomnia in bipolar disorder. It distills the findings from previous mindfulness-based interventions for other disorders that documented beneficial effects for sleep, by concentrating on the most active mindfulness ingredient for treating sleep (the Body Scan). To date, mindfulness based studies have focused on either subjective sleep reports or laboratory-based measures of sleep, both of which have long been called into question because of their lack of ecological validity. This study takes advantage of recent developments in ambulatory sleep monitoring by using the new, FDA approved M1 device, which assesses sleep objectively in a patient's home environment. The M1 device is also the only ambulatory sleep-monitoring device to date that simultaneously assesses both sleep quantity and quality. Finally, this study broadens the view above and beyond sleep and mood and investigates the impact on cognitive and sleep-related psychosocial functioning, both at the end of treatment as well as at a 3-month follow-up. Overall, this work could result in a brief, easy to administer, and easy to disseminate intervention for patients with bipolar disorder with insomnia.
Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is a rare disorder typically characterized by the clinical triad including a sudden onset of fever, painful skin lesions, and neutrophilia. The histopathological findings are a dense neutrophilic infiltrate and oedema of the dermis and epidermis without evidence of a vasculitis. Besides treatment of the underlying cause, sweet syndrome is typically treated with high-dose corticosteroids leading to a relapse-free response in 70% of patients. However, if left unrecognized or untreated, the condition may lead to serious complications. Here, we report on the case of a 38-year-old patient in whom, under the assumption of the presence of necrotizing fasciitis, exarticulation of the right arm was performed. In the absence of pathogen detection and insufficient response to anti-infective therapies, the diagnosis of a sweet syndrome was assumed and, later, confirmed by an excellent response to high-dose administration of systematic glucocorticoids. The case emphasizes the need to be aware of this rare syndrome, which can be easily misdiagnosed due to its close resemblance to infection and stresses the need of further research to define distinct diagnostic tools.
A roll of cloth tape is impregnated with a substrate pref. plaster is for the treatment of wrinkled skin. A length of the tape is dipped in water, or a curative lotion, applied smoothly to the face, and left to dry and harden. It sticks to the skin as it dries and can be worn for several hours. The tape is as easy to apply as sticking plaster, and as easy to remove. Several layers of similar, or different tapes can be superimposed in a single treatment. Application is a substitute for face packs and face masks.
The present invention relates to a cosmetic composition on which triple matrix encapsulation can be performed, and to a method for producing the same. A water-in-oil-type (W/O-type) mono-emulsion is produced by using disteardimonium hectorite and glyceryl monooleate. An oil-in-water-type dual encapsulated emulsion is produced by using sucrose distearate and glyceryl monostearate in the mono-emulsion. Granule particles are produced by mixing any one or more of hydroxy ethyl cellulose, carrageenan, algin, and chitosan in the dual encapsulated emulsion, by performing triple matrix encapsulation, by making a resulting product of the triple matrix encapsulation pass through a nozzle, and by dropping and hardening the same in an ion mixed solution. According to the present invention, stability in the long-term preservation of active ingredients can be remarkably improved, and the outer appearance of the cosmetic composition can be beautifully shown. Active ingredients such as vitamin A, idebenone, rasveratrol, caffeine, adenosine, and niacinamaide are stably encapsulated in water-in-oil-in-water-type dual encapsulated emulsion, so stabilization can be maintained for a long time. Chitosan, hydroxy ethyl cellulose, carrageenan, and algin are encapsulated by a polymer matrix, so triple encapsulation can be performed. When the same is applied to a high functional cosmetic material, effects are maximized, and the outer appearance thereof can be aesthetically beautifully shown.
Tubulointerstitial fibrosis is a classic histologic feature of chronic kidney disease (CKD) in cats and a final common pathway toward end-stage renal disease. Domesticated cats have been used in models of ischemia-induced renal fibrosis. The objective of this study was to evaluate the performance of 2 variations of a transient unilateral renal ischemia and delayed contralateral nephrectomy model of tubulointerstitial fibrosis in cats. Purpose-bred, young adult, domesticated cats underwent 90 min of surgically induced ischemia to the right kidney followed by delayed contralateral nephrectomy performed 21 d (RI-CN21d group; n = 10) or 90 d postischemia (RI-CN90d group; n = 12). Control cats underwent sham surgery followed by left nephrectomy 21 d after (sham-CN group; n = 3). Renal functional parameters, including glomerular filtration rate and serum creatinine concentration, were evaluated before and after surgeries. The right kidneys were harvested 120 d postischemia/ sham. Renal histology with lesion scoring and histomorphometry for quantification of smooth muscle actin immunolabeling and collagen staining were performed on harvested kidneys. Severe acute kidney injury prompted euthanasia after left nephrectomy in 5/10 (50.0%), 2/12 (16.7%), and 0/3 (0%) of cats in the RI-CN21d, RI-CN90d, and sham-CN groups, respectively. A significant decrease in glomerular filtration rate by day 120, relative to baseline, occurred in cats in the RI-CN21d group (P < 0.001) and RI-CN90d group (P < 0.001) but not the sham-CN group (P = 0.76). All but one cat in the ischemia groups were azotemic at the study end. Kidneys subjected to ischemia had higher interstitial inflammation, tubular atrophy, and fibrosis scores compared with sham-operated kidneys. There were significant increases in smooth muscle actin immunolabeling and collagen staining in these kidneys, relative to the contralateral kidneys. In summary, 90 min of unilateral renal ischemia and delayed contralateral nephrectomy induced histologic and biochemical changes consistent with CKD in cats. A 90-d period between ischemia and nephrectomy resulted in improved survivability of the model.
Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
Buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces physical dependence of the opioid type, characterized by withdrawal signs and symptoms upon abrupt discontinuation or rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset. Buprenorphine can be abused in a manner similar to other opioids. This should be considered when prescribing or dispensing buprenorphine in situations when the clinician is concerned about an increased risk of misuse, abuse, or diversion. [see Drug Abuse and Dependence ( )]. 9.3
Study Design

This is a phase I/II study. The phase I portion of the study will determine the maximum tolerated dose of everolimus, rituximab, and bortezomib combination, while the phase II portion will evaluate the depth of responses to the everolimus, rituximab, and bortezomib combination. If patients show response, they will continue on therapy for a total of 6 cycles, and then go on maintenance therapy with everolimus alone until progression. Patients on maintenance will be monitored every 3 months for response. Because of the potential of an IgM flare after rituximab, patients who show an increase in IgM after rituximab in the first 3 months will not be deemed as having progressive disease unless they show evidence of clinical progression and not just an increase of IgM levels. If biochemical progression is confirmed by m-spike, but the participant is clinically benefitting from therapy, the participant may continue on treatment for a few additional points of assessment and re-discuss benefit of therapy. Additionally, if the participant progressed because the treatment was held, participant may remain on study at the discretion of the overall Principal Investigator. Relapse from CR is defined by the reappearance of monoclonal IgM protein and/or recurrence of bone marrow involvement, lymphadenopathy/splenomegaly or symptoms attributable to active disease (Owen et al., 2012). Progression from PR is defined by ≥ 25% increase in IgM level from lowest recorded value and confirmed by a repeat assessment. The development of new signs and symptoms of disease, including Bing Neel syndrome and histological transformation, is also considered as evidence of disease progression. An absolute increase of at least 5 g/l is required to define progression when the IgM level is the only applicable criterion (Owen et al., 2012).
Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Each session will start at 30 minutes in duration and include either high-intensity interval targeting a relative perceived exertion (RPE) of greater than 14 (on a scale of 6-20) or strength training (RPE 12-14) or power walking (RPE 12-14). Each 1 week of supervised sessions will alternate with 1 week of self-directed sessions with mid-week trainer check-in.
PROBLEM TO BE SOLVED: To provide a calcium phosphate cement curing soln. and a cured object compsn. characterized by that the compsn. for a cured object is hardly collapsed even if allowed to fill immediately after kneaded with a powder agent. SOLUTION: A calcium phosphate cement curing soln. composed of an aq. soln. containing 0.5-10wt.%, especially, 0.8-5wt.%, further, 1-4wt.% of a pectin substance such as pectin, pectic acid or pectinic acid is obtained. The pH of this curing soln. is pref. set to 3-5, especially 3.2-3.6 and the viscosity thereof is pref. set to 200dPa.s or less, especially, 20dPa.s, further, 0.5-5dPa.s. As a powder agent, tetracalcium phosphate, calcium hydrogen phosphate, α- tricalcium phosphate, β-tricalcium phosphate and hydroxyapatite can be used. As this powder agent, especially, it is pref. to together use tetracalcium phosphate and calcium hydrogen phosphate in an about equimolar ratio.
UNLABELLED: In 25% of patients presenting with embolic stroke, a cause is not determined. Atrial fibrillation (AF) is a commonly identified mechanism of stroke in this population, particularly in older patients. Conventional investigations are used to detect AF, but can we predict AF in this population and generally? We performed a systematic review to identify potential predictors of AF on 12-lead electrocardiogram (ECG).
METHOD: We conducted a search of EMBASE and Medline databases for prospective and retrospective cohorts, meta-analyses or case-control studies of ECG abnormalities in sinus rhythm predicting subsequent atrial fibrillation. We assessed quality of studies based on the Newcastle-Ottawa scale and data were extracted according to PRISMA guidelines.
RESULTS: We identified 44 studies based on our criteria. ECG patterns that predicted the risk of developing AF included interatrial block, P-wave terminal force lead V1, P-wave dispersion, abnormal P-wave-axis, abnormal P-wave amplitude, prolonged PR interval, left ventricular hypertrophy, QT prolongation, ST-T segment abnormalities and atrial premature beats. Furthermore, we identified that factors such as increased age, high CHADS-VASC, chronic renal disease further increase the positive-predictive value of some of these parameters. Several of these have been successfully incorporated into clinical scoring systems to predict AF.
CONCLUSION: There are several ECG abnormalities that can predict AF both independently, and with improved predictive value when combined with clinical risk factors, and if incorporated into clinical risk scores. Improved and validated predictive models could streamline selection of patients for cardiac monitoring and initiation of oral anticoagulants.
INTRODUCTION: Upper limb and core strength training is essential for older adults to safely perform daily activities. However, existing exercise programmes mainly focus on lower limb strength and are not designed or delivered to suit people with different functional capacities. This study describes the design of a two-arm cluster randomised controlled trial to examine the effects of a multicomponent physical activity (PA) programme, Mobility-Fit, on mobility and frailty in older adults living in care facilities.
METHODS AND ANALYSIS: 160 older adults from 20 care facilities in Hong Kong will be recruited and randomised by care facilities (1:1) to an intervention or a control group. Participants in the intervention group will attend the Mobility-Fit programme, led by facility-based instructors, three times per week, 45 min per session, for 12 weeks, while the control group will participate in a standard care lower limb strengthening programme offered by the care facility. Participants will then be followed up for 9 months. Mobility-Fit comprises agility, postural coordination, balance and strength training, with suitable dosage based on participant's baseline physical and cognitive function. The primary outcomes encompass upper and lower limb strength, trunk stability, reaction time, mobility function and fall efficacy. Secondary outcomes comprise daily PA level and performance, frailty, cognitive function and quality of life. A repeated measures analysis of variance (ANOVA) and generalised estimating equation (GEE) will be used to examine changes in outcomes over time and between groups. Data will be analysed following the intention-to-treat principles. We will also evaluate programme implementation and health economics throughout the follow-up period.
ETHICS AND DISSEMINATION: Ethical approval was acquired in November 2022 from the Joint CUHK-NTEC Clinical Research Ethics Committee in Hong Kong (CREC-2022-459). Informed consent will be obtained from participants. The results of the study will be disseminated through peer-reviewed articles, conference presentations and social media.
TRIAL REGISTRATION NUMBER: ChiCTR2300072709.
The proposed study will perform a randomized, controlled trial (RCT) to compare the effects of three on-line wellness interventions for adults (age 55 years and older) who are experiencing memory and/or cognitive decline. Study participants will be randomly assigned to one of three on-line wellness interventions: (a) Tai Chi, (b) mindful movement course, or (c) health and wellness education course. All interventions will be one hour long, held on-line twice a week for 12 weeks. The co-primary outcomes are 3-month change in cognitive function (Alzheimer's Disease Assessment Scale - cognitive subscale, ADAS-cog) and functional brain connectivity within the default mode network (DMN). Secondary behavioral outcomes will include measures of specific cognitive processes (e.g., auditory memory, executive function, processing speed), physical function (e.g., mobility), anxiety, depression, fatigue, pain, sleep quality, social activities/social isolation, and quality of life. Secondary neuroimaging outcomes will include measures of functional connectivity in other intrinsic brain networks (e.g., salience, central executive, language), cerebral perfusion, and structural white matter integrity. The behavioral and imaging outcomes will be assessed at baseline and upon completion of the 12-week interventions. To assess durability of the behavioral effects of the interventions, the cognitive and behavioral outcomes will be assessed again 6 months after the completion of the interventions.